TRCT
AMRX icon

Tower Research Capital (TRC)’s Amneal Pharmaceuticals AMRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Buy
15,141
+9,600
+173% +$132K 0.01% 1493
2026
Q1 		$68.9K Sell
5,541
-8,429
-60% -$113K ﹤0.01% 2477
2025
Q4 		$176K Buy
13,970
+9,261
+197% +$106K ﹤0.01% 1536
2025
Q3 		$47.1K Sell
4,709
-13,059
-73% -$117K ﹤0.01% 2570
2025
Q2 		$144K Buy
17,768
+14,855
+510% +$112K ﹤0.01% 2082
2025
Q1 		$24.4K Buy
2,913
+1,136
+64% +$9.48K ﹤0.01% 2784
2024
Q4 		$14.1K Buy
1,777
+974
+121% +$8.17K ﹤0.01% 3481
2024
Q3 		$6.68K Sell
803
-26,786
-97% -$209K ﹤0.01% 4118
2024
Q2 		$175K Buy
27,589
+24,671
+845% +$157K ﹤0.01% 2177
2024
Q1 		$17.7K Sell
2,918
-31,516
-92% -$178K ﹤0.01% 3106
2023
Q4 		$209K Buy
34,434
+29,775
+639% +$133K ﹤0.01% 2070
2023
Q3 		$19.7K Sell
4,659
-6,506
-58% -$24.3K ﹤0.01% 3391
2023
Q2 		$34.6K Buy
11,165
+6,089
+120% +$13K ﹤0.01% 2893
2023
Q1 		$7K Sell
5,076
-3,363
-40% -$6.7K ﹤0.01% 4711
2022
Q4 		$17K Buy
8,439
+1,077
+15% +$2.41K ﹤0.01% 3257
2022
Q3 		$15K Buy
7,362
+484
+7% +$1.36K ﹤0.01% 4150
2022
Q2 		$22K Buy
6,878
+4,529
+193% +$16.4K ﹤0.01% 3681
2022
Q1 		$9K Sell
2,349
-275
-10% -$1.22K ﹤0.01% 4426
2021
Q4 		$13K Sell
2,624
-7,491
-74% -$37.3K ﹤0.01% 4145
2021
Q3 		$54K Sell
10,115
-5,028
-33% -$25.3K ﹤0.01% 2890
2021
Q2 		$78K Buy
15,143
+5,184
+52% +$29.5K ﹤0.01% 2624
2021
Q1 		$67K Sell
9,959
-32,711
-77% -$181K ﹤0.01% 2879
2020
Q4 		$195K Sell
42,670
-96,662
-69% -$428K 0.01% 1724
2020
Q3 		$540K Buy
139,332
+104,203
+297% +$446K 0.01% 1598
2020
Q2 		$167K Buy
+35,129
New +$145K 0.01% 1959
2019
Q4 		– Sell
-5,413
Closed -$16K – 3477
2019
Q3 		$16K Sell
5,413
-2,353
-30% -$8.21K ﹤0.01% 2601
2019
Q2 		$56K Buy
7,766
+6,894
+791% +$70.5K ﹤0.01% 1519
2019
Q1 		$12K Sell
872
-828
-49% -$10.9K ﹤0.01% 2559
2018
Q4 		$23K Buy
+1,700
New +$30.6K ﹤0.01% 1813

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Tower Research Capital (TRC)'s AMRX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Amneal Pharmaceuticals (AMRX) stake by 173% in Q2 2026, buying an estimated $132K and bringing the position to 15,141 shares worth $262K. The position accounts for 0.01% of the portfolio, ranked #1493.

Tower Research Capital (TRC) first reported a position in AMRX in Q4 2018 and has held it in 29 quarters since. The position peaked at $540K in Q3 2020. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Tower Research Capital (TRC) held 15,141 shares of Amneal Pharmaceuticals worth $262K as of Q2 2026.
  • Tower Research Capital (TRC) bought 9,600 Amneal Pharmaceuticals shares in Q2 2026, an estimated $132K.
  • Amneal Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1493 holding.
  • Tower Research Capital (TRC) first reported a position in Amneal Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Amneal Pharmaceuticals position peaked at $540K in Q3 2020.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.